Compare PM & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PM | TMO |
|---|---|---|
| Founded | 1987 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8B | 216.4B |
| IPO Year | N/A | N/A |
| Metric | PM | TMO |
|---|---|---|
| Price | $149.44 | $574.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 20 |
| Target Price | $190.44 | ★ $626.21 |
| AVG Volume (30 Days) | ★ 5.3M | 1.6M |
| Earning Date | 10-21-2025 | 01-29-2026 |
| Dividend Yield | ★ 3.93% | 0.30% |
| EPS Growth | N/A | ★ 8.54 |
| EPS | 5.52 | ★ 17.32 |
| Revenue | $39,992,000,000.00 | ★ $43,736,000,000.00 |
| Revenue This Year | $10.82 | $4.33 |
| Revenue Next Year | $7.66 | $4.94 |
| P/E Ratio | ★ $27.12 | $33.14 |
| Revenue Growth | ★ 7.45 | 3.22 |
| 52 Week Low | $116.12 | $385.46 |
| 52 Week High | $186.69 | $610.97 |
| Indicator | PM | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 51.55 |
| Support Level | $146.65 | $561.91 |
| Resistance Level | $150.89 | $575.25 |
| Average True Range (ATR) | 3.22 | 12.06 |
| MACD | -0.60 | -3.65 |
| Stochastic Oscillator | 25.97 | 33.58 |
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).